Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1
Completed
Conditions
Lung Cancer
First Posted Date
2003-01-27
Last Posted Date
2019-03-13
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
12
Registration Number
NCT00025480
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

Phase 2
Completed
Conditions
Esophageal Cancer
First Posted Date
2003-01-27
Last Posted Date
2014-05-09
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
21
Registration Number
NCT00021320
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-06-19
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT00052351
Locations
🇺🇸

Center for Cancer Research, Bethesda, Maryland, United States

🇺🇸

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
21
Registration Number
NCT00005819
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Phase 1
Completed
Conditions
Head and Neck Cancer
First Posted Date
2003-01-27
Last Posted Date
2010-06-10
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
12
Registration Number
NCT00005647
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2010-05-14
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00027937
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2
Conditions
Breast Cancer
First Posted Date
2003-01-27
Last Posted Date
2008-07-24
Lead Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Registration Number
NCT00006120
Locations
🇫🇷

Centre D'Oncologie Du Pays-Basque, Bayonne, France

🇫🇷

Hopital Intercommunal De Creteil, Creteil, France

🇫🇷

Centre Hospitalier d'Antibes, Antibes, France

and more 32 locations

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

First Posted Date
2003-01-27
Last Posted Date
2015-08-26
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
33
Registration Number
NCT00002854
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

First Posted Date
2003-01-27
Last Posted Date
2024-04-02
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
41
Registration Number
NCT00003042
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer

First Posted Date
2003-01-27
Last Posted Date
2017-07-31
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
82
Registration Number
NCT00006110
Locations
🇺🇸

Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

🇺🇸

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy